Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)
Year: 2013
Type: article
Abstract: The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4(th) European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists.
Source: Haematologica
Authors: D. Averbuch, C. Cordonnier, D. M. Livermore, M. Mikulska, C. Orasch, C. Viscoli, I. C. Gyssens, W. V. Kern, G. Klyasova, O. Marchetti, D. Engelhard, M. Akova, on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN
Institutions: Hadassah Medical Center, Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, University of East Anglia, Ospedale Policlinico San Martino, University of Genoa, Centre Hospitalier Universitaire Vaudois, Radboud University Nijmegen, Radboud University Medical Center, Canisius-Wilhelmina Ziekenhuis, Hasselt University, University of Freiburg, University Medical Center Freiburg, National Medical Research Center for Hematology, Hacettepe University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: multidrug-resistant bacteria, carbapenemase-producing Gram-negative bacteria, leukemia patients, hematopoietic stem cell transplant recipients, colistin, polymyxin B, tigecycline, fosfomycin, linezolid, combination antibiotic therapy, risk-benefit assessment, antimicrobial susceptibility testing, pharmacokinetics/pharmacodynamics
Open Access status: gold
Estimated APC paid: $2,157
Funders: Pfizer, Gilead Sciences, Astellas Pharma
OpenAlex ID: W2132286831
